Cite
HARVARD Citation
Procopio, G. et al. (2023). A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). Tumori. 109 (1), pp. 129-137. [Online].